Teleflex (NYSE:TFX) Posts Quarterly Earnings Results, Beats Expectations By $0.48 EPS

Teleflex (NYSE:TFX) released its quarterly earnings results on Thursday. The medical technology company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48, FiscalAI reports. The firm had revenue of $570.33 million for the quarter, compared to analyst estimates of $559.59 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The company’s revenue for the quarter was up 28.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.73 earnings per share. Teleflex updated its FY 2026 guidance to 6.900-7.200 EPS.

Here are the key takeaways from Teleflex’s conference call:

• Second-quarter results exceeded expectations, with pro forma adjusted constant-currency revenue growth of 4.7% and adjusted EPS of $1.76, supported by strong vascular and surgical performance.
• Teleflex lowered its 2026 revenue-growth outlook to 3.5%-4.5% from 4.5%-5.5%, primarily because integration of the Vascular Intervention acquisition is taking longer than expected and is now expected to continue through the second half of the year.
• The company raised 2026 adjusted EPS guidance to $6.90-$7.20 from $6.25-$6.55, reflecting share repurchases, lower projected interest expense, and a reduced tax-rate outlook, while maintaining an adjusted operating-margin outlook of approximately 19%.
• Teleflex closed the OEM divestiture for approximately $1.5 billion in proceeds and used much of the after-tax proceeds to repay $700 million of debt; it also plans to begin an additional $250 million accelerated share repurchase and remains committed to $1 billion of buybacks and $800 million of debt reduction.
• Innovation milestones included FDA approval of EZPLAZ freeze-dried plasma and continued progress for the Freesolve resorbable magnesium scaffold, including early completion of BIOMAG-II enrollment and commencement of the U.S. pivotal BIOMAG-III trial.

Teleflex Trading Up 2.1%

TFX traded up $2.83 during mid-day trading on Thursday, reaching $139.61. The stock had a trading volume of 1,301,231 shares, compared to its average volume of 482,291. The firm’s fifty day simple moving average is $131.61 and its two-hundred day simple moving average is $122.46. The stock has a market capitalization of $6.18 billion, a P/E ratio of -6.12, a P/E/G ratio of 1.02 and a beta of 0.81. Teleflex has a 52 week low of $100.18 and a 52 week high of $145.00. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Friday, August 14th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, August 14th. Teleflex’s dividend payout ratio (DPR) is presently -5.96%.

Analysts Set New Price Targets

TFX has been the subject of several research analyst reports. Wall Street Zen downgraded Teleflex from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. Bank of America upgraded Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 target price on the stock in a report on Monday, April 13th. Truist Financial restated a “hold” rating and issued a $143.00 target price (up from $135.00) on shares of Teleflex in a research note on Monday, May 11th. Raymond James Financial reaffirmed an “outperform” rating and issued a $150.00 price target on shares of Teleflex in a report on Friday, May 8th. Finally, Zacks Research upgraded shares of Teleflex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $148.90.

Hedge Funds Weigh In On Teleflex

Several large investors have recently made changes to their positions in the company. Invesco Ltd. raised its holdings in Teleflex by 3.0% during the 4th quarter. Invesco Ltd. now owns 162,882 shares of the medical technology company’s stock worth $19,878,000 after purchasing an additional 4,807 shares during the last quarter. Alberta Investment Management Corp bought a new position in shares of Teleflex in the 4th quarter valued at about $1,318,000. Vident Advisory LLC grew its position in shares of Teleflex by 2.8% during the 4th quarter. Vident Advisory LLC now owns 6,992 shares of the medical technology company’s stock worth $853,000 after buying an additional 188 shares during the period. State of Tennessee Department of Treasury grew its position in shares of Teleflex by 4.7% during the 4th quarter. State of Tennessee Department of Treasury now owns 22,374 shares of the medical technology company’s stock worth $2,731,000 after buying an additional 998 shares during the period. Finally, Fuller & Thaler Asset Management Inc. raised its stake in shares of Teleflex by 21.3% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 696,950 shares of the medical technology company’s stock worth $85,056,000 after buying an additional 122,481 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Key Stories Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Quarterly results exceeded expectations. Teleflex reported second-quarter adjusted EPS of $1.76, topping the $1.28 consensus estimate, while revenue of $570.3 million surpassed expectations of $559.6 million. Revenue rose 28.9% year over year, providing the main catalyst for the stock’s upward move. Teleflex Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Full-year earnings guidance was raised above analyst expectations. Teleflex forecast fiscal 2026 EPS of $6.90 to $7.20, compared with the $6.70 consensus estimate. Revenue guidance of approximately $2.3 billion was broadly in line with expectations, suggesting the earnings upside is being driven primarily by profitability and execution. Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
• Positive Sentiment: Teleflex declared a quarterly dividend. Shareholders of record on August 14 will receive $0.34 per share on September 30. The dividend provides an annualized payout of approximately $1.36 per share and a yield of about 1%, adding modest shareholder-return support.
• Neutral Sentiment: Profitability remains mixed. GAAP diluted EPS from continuing operations was $0.96, down from $1.54 a year earlier, and the company reported a negative net margin. The adjusted EPS beat and higher outlook outweighed these concerns for investors, but the year-over-year decline remains a risk to monitor. Teleflex Posts Strong Q2 2026 Results

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.